Previous studies have reported that EGFR and ALK double mutations have been found in the minority of patients with non-small-cell lung cancer (Koivunen et al., 2008), in which patients with double mutations have shorter OS values than patients with EGFR or ALK single mutations (Lou et al., 2016). Here, EGFR is linked to non-small cell lung carcinoma.